1.51
price up icon1.34%   0.02
after-market Handel nachbörslich: 1.53 0.02 +1.32%
loading
Schlusskurs vom Vortag:
$1.49
Offen:
$1.49
24-Stunden-Volumen:
804.45K
Relative Volume:
1.00
Marktkapitalisierung:
$92.70M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.4887
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+2.03%
1M Leistung:
-5.03%
6M Leistung:
+6.34%
1J Leistung:
-89.00%
1-Tages-Spanne:
Value
$1.47
$1.5694
1-Wochen-Bereich:
Value
$1.45
$1.59
52-Wochen-Spanne:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Firmenname
Pliant Therapeutics Inc
Name
Telefon
650-481-6770
Name
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
171
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PLRX's Discussions on Twitter

Vergleichen Sie PLRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.51 91.47M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-10 Herabstufung JP Morgan Neutral → Underweight
2025-03-04 Fortgesetzt Cantor Fitzgerald Neutral
2025-03-04 Herabstufung Needham Buy → Hold
2025-03-03 Herabstufung Leerink Partners Outperform → Market Perform
2025-03-03 Herabstufung Stifel Buy → Hold
2025-02-10 Herabstufung Canaccord Genuity Buy → Hold
2025-02-10 Herabstufung Citigroup Buy → Neutral
2025-02-10 Herabstufung H.C. Wainwright Buy → Neutral
2025-02-10 Herabstufung JP Morgan Overweight → Neutral
2025-02-10 Herabstufung Oppenheimer Outperform → Perform
2025-02-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2025-02-10 Herabstufung Wells Fargo Overweight → Equal Weight
2024-09-09 Fortgesetzt Leerink Partners Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-05-18 Eingeleitet Canaccord Genuity Buy
2023-04-13 Eingeleitet Robert W. Baird Outperform
2022-12-14 Eingeleitet Stifel Buy
2022-12-07 Eingeleitet JP Morgan Overweight
2022-09-01 Eingeleitet Citigroup Buy
2022-07-20 Eingeleitet SVB Leerink Outperform
2022-05-25 Eingeleitet Cantor Fitzgerald Overweight
2021-12-10 Eingeleitet Oppenheimer Outperform
2021-11-24 Eingeleitet RBC Capital Mkts Outperform
2021-11-03 Eingeleitet H.C. Wainwright Buy
2021-04-20 Eingeleitet BTIG Research Buy
2021-04-05 Eingeleitet Citigroup Buy
2020-06-29 Eingeleitet Citigroup Buy
2020-06-29 Eingeleitet Cowen Outperform
2020-06-29 Eingeleitet Needham Buy
2020-06-29 Eingeleitet Piper Sandler Overweight
Alle ansehen

Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten

pulisher
07:06 AM

Does Pliant Therapeutics Inc. stock trade at a discount to peersQuarterly Performance Summary & Community Verified Watchlist Alerts - newser.com

07:06 AM
pulisher
05:50 AM

How Pliant Therapeutics Inc. (9PT) stock reacts to new regulationsJuly 2025 News Drivers & Risk Managed Investment Strategies - newser.com

05:50 AM
pulisher
05:25 AM

What to expect from Pliant Therapeutics Inc. in the next 30 days2025 Winners & Losers & Fast Exit and Entry Strategy Plans - newser.com

05:25 AM
pulisher
02:18 AM

Technical signs of recovery in Pliant Therapeutics Inc.Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com

02:18 AM
pulisher
02:12 AM

Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Action & Verified Swing Trading Watchlist - newser.com

02:12 AM
pulisher
Oct 13, 2025

Pliant Therapeutics Inc. stock trend forecast2025 Investor Takeaways & Capital Efficiency Focused Strategies - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Has Pliant Therapeutics Inc. found a price floorJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Will Pliant Therapeutics Inc. bounce back from current supportJuly 2025 PostEarnings & Community Consensus Trade Alerts - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Price momentum metrics for Pliant Therapeutics Inc. explainedJuly 2025 Breakouts & Free Community Consensus Stock Picks - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Can you recover from losses in Pliant Therapeutics Inc.Volume Spike & Weekly Watchlist of Top Performers - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

What analysts say about Pliant Therapeutics Inc stockDividend Cut Warnings & Low Risk Investment Plans - earlytimes.in

Oct 11, 2025
pulisher
Oct 11, 2025

Pliant Therapeutics' (PLRX) Underweight Rating Reiterated at JPMorgan Chase & Co. - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

JPMorgan downgrades Pliant Therapeutics stock rating to Underweight from Neutral - Investing.com Canada

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics Shares Fall After JPMorgan Downgrade - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics Inc. stock outlook for YEARMarket Growth Review & Capital Protection Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha

Oct 10, 2025
pulisher
Oct 10, 2025

JPMorgan Downgrades Pliant Therapeutics to Underweight From Neutral - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

PLRX Downgraded by JP Morgan: Today's Key Analyst Rating Update - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Order flow analysis tools used on Pliant Therapeutics Inc.July 2025 Intraday Action & Community Consensus Stock Picks - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics (NASDAQ:PLRX) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Is Pliant Therapeutics Inc. (9PT) stock testing key supportPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Pliant Therapeutics Inc. (9PT) stock a top pick for value investorsGlobal Markets & Free Reliable Trade Execution Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Detecting price anomalies in Pliant Therapeutics Inc. with AIJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Evaluating Pliant Therapeutics Inc. with trendline analysis2025 Volume Leaders & High Conviction Investment Ideas - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Why Pliant Therapeutics Inc. (9PT) stock attracts wealthy investorsJuly 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com

Oct 06, 2025
pulisher
Oct 03, 2025

How sustainable is Pliant Therapeutics Inc. stock dividend payoutJobs Report & Free Technical Pattern Based Buy Signals - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Published on: 2025-10-03 01:17:50 - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Applying big data sentiment scoring on Pliant Therapeutics Inc.Gold Moves & Low Risk High Reward Trade Ideas - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Technical analysis overview for Pliant Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com

Oct 01, 2025

Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '25
Sale
11.20
20,148
225,680
262,608
Hull Hans
Chief Business Officer
Jan 17 '25
Sale
11.20
15,936
178,501
211,558
Lefebvre Eric
Chief Medical Officer
Jan 17 '25
Sale
11.20
18,478
206,974
194,574
Cheung Lily
Chief Human Resource Officer
Jan 17 '25
Sale
11.20
3,740
41,892
24,550
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '25
Sale
11.20
13,270
148,639
80,774
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 22 '25
Sale
10.99
10,230
112,462
70,544
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):